Healthline Reports on Sustained Low-Dose 'Microdosing' GLP-1 Real-World Analysis: 5.5% Mean Body Weight Loss at 12 Months on Low-Dose Tirzepatide, 2.2% on Low-Dose Semaglutide With Fewer GI Side Effects
Healthline published Friday September 18, 2026 an analysis of an emerging real-world usage pattern in which patients remain on the lowest starting doses of GLP-1 receptor agonists — tirzepatide (Zepbound/Mounjaro) or semaglutide (Wegovy/Ozempic) — for extended periods rather than titrating to full therapeutic doses. The published research summarized in the article: at 12 months, sustained low-dose tirzepatide produced a 5.5% mean body weight reduction, while sustained low-dose semaglutide produced a 2.2% mean reduction. Both figures fall well below full-titration Phase 3 comparators (Wegovy STEP 1 13.7%, SURMOUNT-5 tirzepatide 20.2% at 72 weeks) but sustained low-dose semaglutide was associated with lower rates of nausea, vomiting, and other GI adverse events. The 'microdosing' pattern is not FDA-labeled dosing and reflects patient-and-prescriber choices driven by cost (compounded and telehealth pricing), tolerability, or maintenance-phase preferences. Real-world evidence on the durability of these smaller-than-labeled reductions remains preliminary.